Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC).

6. Juni 2013

Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013.

Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01

Abstract